ARCHIVES

ODAC Recommends Iressa Approval As Third-Line Lung Cancer Treatment

This article is from The Cancer Letter archive.

Vol. 28 No. 35 | September 27, 2002

Download PDF Visit The Full Archive

Related Articles

CMS To Recognize NCCN’s Drug Compendium.

June 6, 2008

Where’s The Money for Local Programs? Everyone Wants To Know

February 28, 1975

Guest Editorial By Gregory Reaman: Memories Of A Merger Past

July 15, 2011

ESAs Increase Risk of Death by 11 Percent, Blood Clots by 59 Percent, Meta-Analysis Finds; Study To Be Updated At ASCO.

June 1, 2007

Risks Of Long-Term HRT Outweigh Benefits, WHI Finds

March 28, 2008

Group Chairmen Reject DCT’s Agenda For Clinical Trials Review, demand Right To Select Speakers

June 30, 1978